دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Industry Payments to Rheumatologists Ought to Be Going Down, Not Up
Aaron P. Mitchell
doi : 10.1002/art.41898
Volume 73, Issue 11 p. 1951-1953
Is There a Place for Chimeric Antigen Receptor–T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
Cindy Orvain,Morgane Boulch,Philippe Bousso,Yannick Allanore,Jérôme Avouac
doi : 10.1002/art.41812
Volume 73, Issue 11 p. 1954-1965
Chimeric antigen receptor–T (CAR-T) cell therapy is based on specific targeting of tumor antigens, leading to lysis and destruction of tumor cells. The high potency of CAR-T cells in the management of B cell malignancies has been demonstrated. Following the success of this therapeutic strategy, new CAR-T cell–derived constructs that have the ability to eradicate pathogenic B cells or restore tolerance have been developed. The present review discusses how the knowledge and technology generated by the use of CAR-T cells may be translated and integrated into ongoing therapeutic strategies for autoimmune rheumatic diseases. To this end, we describe the details of CAR-T cell technology, as well as the meaningful achievements attained with the use of CAR-T cells in onco-hematology. In addition, we review the preliminary data obtained with CAR-T cells and their derivative constructs in experimental models of autoimmune diseases. Finally, we focus on how CAR-T cell engineering interferes with the pathogenesis of 3 chronic autoimmune rheumatic diseases—rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis—and discuss whether these constructs might yield greater efficacy and be associated with fewer adverse events compared to current treatment strategies.
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
Chiara Trincianti,Evert Hendrik Pieter Van Dijkhuizen,Alessandra Alongi,Marta Mazzoni,Joost F. Swart,Irina Nikishina,Pekka Lahdenne,Lidia Rutkowska-Sak,Tadej Avcin,Pierre Quartier,Violeta Panaviene,Yosef Uziel,Chris Pruunsild,Veronika Vargova,Soamarat Vilaiyuk,Pavla Dolezalova,Sarah Ringold,Marco Garrone,Nicolino Ruperto,Angelo Ravelli,Alessandro Consolaro,for the Paediatric Rheumatology International Trials Organisation
doi : 10.1002/art.41879
Volume 73, Issue 11 p. 1966-1975
To develop and validate new Juvenile Arthritis Disease Activity Score 10 (JADAS10) and clinical JADAS10 (cJADAS10) cutoffs to separate the states of inactive disease (ID), minimal disease activity (MiDA), moderate disease activity (MoDA), and high disease activity (HDA) in children with oligoarthritis and with rheumatoid factor–negative polyarthritis, based on subjective disease assessment by the treating pediatric rheumatologist.
Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality
Nicolas Gendron,Marie-Agnès Dragon-Durey,Richard Chocron,Luc Darnige,Georges Jourdi,Aurélien Philippe,Camille Chenevier-Gobeaux,Jérôme Hadjadj,Jérôme Duchemin,Lina Khider,Nader Yatim,Guillaume Goudot,Daphné Krzisch,Benjamin Debuc,Laetitia Mauge,Françoise Levavasseur,Frédéric Pene,Jeremy Boussier,Elise Sourdeau,Julie Brichet,Nadège Ochat,Claire Goulvestre,Christophe Peronino,Tali-Anne Szwebel,Franck Pages,Pascale Gaussem,Charles-Marc Samama,Cherifa Cheurfa,Benjamin Planquette,Olivier Sanchez,Jean-Luc Diehl,Tristan Mirault,Michaela Fontenay,Benjamin Terrier,David M. Smadja
doi : 10.1002/art.41777
Volume 73, Issue 11 p. 1976-1985
The clinical relevance of antiphospholipid antibodies (aPLs) in COVID-19 is controversial. This study was undertaken to investigate the prevalence and prognostic value of conventional and nonconventional aPLs in patients with COVID-19.
Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
Johanna M. Kroese,Bernd W. Brandt,Mark J. Buijs,Wim Crielaard,Frank Lobbezoo,Bruno G. Loos,Laurette van Boheemen,Dirkjan van Schaardenburg,Egija Zaura,Catherine M. C. Volgenant
doi : 10.1002/art.41780
Volume 73, Issue 11 p. 1986-1993
It has been suggested that rheumatoid arthritis (RA) may originate at the oral mucosa. The aim of the present study was to assess the oral microbiome and periodontal condition in patients with early RA and individuals at risk of developing RA compared to healthy controls.
Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank
Lauren Prisco,Matthew Moll,Jiaqi Wang,Brian D. Hobbs,Weixing Huang,Lily W. Martin,Vanessa L. Kronzer,Sicong Huang,Edwin K. Silverman,Tracy J. Doyle,Michael H. Cho,Jeffrey A. Sparks
doi : 10.1002/art.41791
Volume 73, Issue 11 p. 1994-2002
To investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.
Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor
Katrien Van Raemdonck,Sadiq Umar,Karol Palasiewicz,Michael V. Volin,Hatem A. Elshabrawy,Bianca Romay,Chandana Tetali,Azam Ahmed,M. Asif Amin,Ryan K. Zomorrodi,Nadera Sweiss,Shiva Shahrara
doi : 10.1002/art.41792
Volume 73, Issue 11 p. 2003-2014
In rheumatoid arthritis (RA), elevated serum interleukin-34 (IL-34) levels are linked with increased disease severity. IL-34 binds to 2 receptors, macrophage colony-stimulating factor receptor (M-CSFR) and syndecan 1, which are coexpressed in RA macrophages. Expression of both IL-34 and syndecan 1 is strikingly elevated in the RA synovium, yet their mechanisms of action remain undefined. This study was undertaken to investigate the mechanism of action of IL-34 in RA.
Erosive Hand Osteoarthritis: Incidence and Predictive Characteristics Among Participants in the Osteoarthritis Initiative
Timothy E. McAlindon,Jeffrey B. Driban,Mary B. Roberts,Jeffrey Duryea,Ida K. Haugen,Lena F. Schaefer,Stacy E. Smith,Alexander Mathiessen,Charles Eaton
doi : 10.1002/art.41757
Volume 73, Issue 11 p. 2015-2024
To evaluate age, sex, race, osteoarthritis (OA) severity, metabolic factors, and bone health as risk factors for erosive hand OA at baseline and its incidence over a 48-month period.
The CRTAC1 Protein in Plasma Is Associated With Osteoarthritis and Predicts Progression to Joint Replacement: A Large-Scale Proteomics Scan in Iceland
Unnur Styrkarsdottir,Sigrun H. Lund,Saedis Saevarsdottir,Magnus I. Magnusson,Kristbjorg Gunnarsdottir,Gudmundur L. Norddahl,Michael L. Frigge,Erna V. Ivarsdottir,Gyda Bjornsdottir,Hilma Holm,Gudmundur Thorgeirsson,Thorunn Rafnar,Ingileif Jonsdottir,Thorvaldur Ingvarsson,Helgi Jonsson,Patrick Sulem,Unnur Thorsteinsdottir,Daniel Gudbjartsson,Kari Stefansson
doi : 10.1002/art.41793
Volume 73, Issue 11 p. 2025-2034
Biomarkers for diagnosis and progression of osteoarthritis (OA) are lacking. This study was undertaken to identify circulating biomarkers for OA that could predict disease occurrence and/or progression to joint replacement.
Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial
Yuanyuan Wang,Graeme Jones,Catherine Hill,Anita E. Wluka,Andrew B. Forbes,Andrew Tonkin,Sultana Monira Hussain,Changhai Ding,Flavia M. Cicuttini
doi : 10.1002/art.41760
Volume 73, Issue 11 p. 2035-2043
To determine whether atorvastatin slows tibial cartilage volume loss in patients with symptomatic knee osteoarthritis (OA) in a multicenter, randomized, double-blind, placebo-controlled trial.
Incorrect Versions of Supplementary Tables 4 and 5 and Errors in Safety Data and in Table 1 in the Article by Merrill et al (Arthritis Rheumatol, February 2018)
doi : 10.1002/art.41995
Volume 73, Issue 11 p. 2043-2043
Minus Signs Inadvertently Inserted for Two 95% Confidence Interval Values in the Article by Steen Pettersen et al (Arthritis Rheumatol, July 2019)
doi : 10.1002/art.41996
Volume 73, Issue 11 p. 2043-2043
The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral Spondyloarthritis
Thomas Renson,Philippe Carron,Ann-Sophie De Craemer,Liselotte Deroo,Manouk de Hooge,Simon Krabbe,Lennart Jans,Mikkel Østergaard,Dirk Elewaut,Filip Van den Bosch
doi : 10.1002/art.41783
Volume 73, Issue 11 p. 2044-2051
This study was undertaken to assess the inflammatory burden in peripheral spondyloarthritis (SpA) by magnetic resonance imaging (MRI) of the legs in an early remission–induction strategy study of tumor necrosis factor (TNF) blockade. Furthermore, we sought to determine the value of MRI to predict disease relapse versus sustained remission after treatment discontinuation.
Progressive Pseudorheumatoid Dysplasia—Radiographic Evolution Over Twenty Years
Jacopo Ciaffi,Giancarlo Facchini,Marco Miceli,Elena Borlandelli,Riccardo Meliconi,Francesco Ursini
doi : 10.1002/art.41815
Volume 73, Issue 11 p. 2051-2051
Estrogen-Induced hsa-miR-10b-5p Is Elevated in T Cells From Patients With Systemic Lupus Erythematosus and Down-Regulates Serine/Arginine-Rich Splicing Factor 1
Suruchi A. Ramanujan,Elena N. Cravens,Suzanne M. Krishfield,Vasileios C. Kyttaris,Vaishali R. Moulton
doi : 10.1002/art.41787
Volume 73, Issue 11 p. 2052-2058
Autoimmune diseases affect women disproportionately more than men. Estrogen is implicated in immune cell dysfunction, yet its precise molecular roles are not fully known. We recently identified new roles for serine/arginine-rich splicing factor 1 (SRSF1) in T cell function and autoimmunity. SRSF1 levels are decreased in T cells from patients with systemic lupus erythematosus (SLE) and are associated with active disease and comorbidity. However, the molecular mechanisms that control SRSF1 expression are unknown. Srsf1 messenger RNA (mRNA) has a long 3?-untranslated region (3?-UTR), suggesting posttranscriptional control. This study was undertaken to investigate the role of estrogen and posttranscriptional mechanisms of SRSF1 regulation in T cells and SLE.
What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
Richard Furie,Eric F. Morand,Ian N. Bruce,David Isenberg,Ronald van Vollenhoven,Gabriel Abreu,Lilia Pineda,Raj Tummala
doi : 10.1002/art.41778
Volume 73, Issue 11 p. 2059-2068
The British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials. To understand the relevance of BICLA in clinical practice, we investigated relationships between BICLA response and routine SLE assessments, patient-reported outcomes (PROs), and medical resource utilization.
Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus
Inês Alves,Beatriz Santos-Pereira,Hans Dalebout,Sofia Santos,Manuel M. Vicente,Ana Campar,Michel Thepaut,Franck Fieschi,Sabine Strahl,Fanny Boyaval,Ramon Vizcaíno,Roberto Silva,Stephanie Holst-Bernal,Carlos Vasconcelos,Lélita Santos,Manfred Wuhrer,António Marinho,Bram Heijs,Salomé S. Pinho
doi : 10.1002/art.41768
Volume 73, Issue 11 p. 2069-2077
Changes in protein glycosylation are a hallmark of immune-mediated diseases. Glycans are master regulators of the inflammatory response and are important molecules in self–nonself discrimination. This study was undertaken to investigate whether lupus nephritis (LN) exhibits altered cellular glycosylation to identify a unique glycosignature that characterizes LN pathogenesis.
Rice Bodies in Cinematic Rendering
Jian Liu,Xinge Cheng,Rongpin Wang,Xianchun Zeng
doi : 10.1002/art.41890
Volume 73, Issue 11 p. 2077-2077
Prevalence of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis and Spatial Association With Quarries in a Region of Northeastern France: A Capture–Recapture and Geospatial Analysis
Stéphane Giorgiutti,Yannick Dieudonne,Olivier Hinschberger,Benoît Nespola,Julien Campagne,Hanta Nirina Rakotoarivelo,Thierry Hannedouche,Bruno Moulin,Gilles Blaison,Jean-Christophe Weber,Marie-Caroline Dalmas,Frédéric De Blay,Dan Lipsker,François Chantrel,Jacques-Eric Gottenberg,Yves Dimitrov,Olivier Imhoff,Pierre-Edouard Gavand,Emmanuel Andres,Christian Debry,Yves Hansmann,Alexandre Klein,Caroline Lohmann,François Mathiaux,Aurélien Guffroy,Vincent Poindron,Thierry Martin,Anne-Sophie Korganow,Laurent Arnaud
doi : 10.1002/art.41767
Volume 73, Issue 11 p. 2078-2085
Silica is an environmental substance strongly linked with autoimmunity. The aim of this study was to assess the prevalence of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal limited vasculitis, in a northeastern region of France and to evaluate whether there was a geospatial association between the localization of quarries in the region and the prevalence of these AAVs.
B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis
Hiroko Numajiri,Ai Kuzumi,Takemichi Fukasawa,Satoshi Ebata,Asako Yoshizaki-Ogawa,Yoshihide Asano,Yutaka Kazoe,Kazuma Mawatari,Takehiko Kitamori,Ayumi Yoshizaki,Shinichi Sato
doi : 10.1002/art.41798
Volume 73, Issue 11 p. 2086-2095
We undertook this study to investigate the effect of B cell depletion on fibrosis in systemic sclerosis (SSc) and its mechanism of action.
Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization
Natalie McCormick,Mark J. O’Connor,Chio Yokose,Tony R. Merriman,David B. Mount,Aaron Leong,Hyon K. Choi
doi : 10.1002/art.41779
Volume 73, Issue 11 p. 2096-2104
Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated. We undertook this study to investigate the potential causal nature and direction between insulin resistance and hyperuricemia, along with gout, by using bidirectional Mendelian randomization (MR) analyses.
Augmentation of Stimulator of Interferon Genes–Induced Type I Interferon Production in COPA Syndrome
Takashi Kato,Masaki Yamamoto,Yoshitaka Honda,Takashi Orimo,Izumi Sasaki,Kohei Murakami,Hiroaki Hemmi,Yuri Fukuda-Ohta,Kyoichi Isono,Saki Takayama,Hidenori Nakamura,Yoshiro Otsuki,Toshiaki Miyamoto,Junko Takita,Takahiro Yasumi,Ryuta Nishikomori,Tadashi Matsubayashi,Kazushi Izawa,Tsuneyasu Kaisho
doi : 10.1002/art.41790
Volume 73, Issue 11 p. 2105-2115
Coatomer subunit alpha (COPA) syndrome, also known as autoinflammatory interstitial lung, joint, and kidney disease, is caused by heterozygous mutations in COPA. We identified a novel COPA variant in 4 patients in one family. We undertook this study to elucidate whether and how the variant causes manifestations of COPA syndrome by studying these 4 patients and by analyzing results from a gene-targeted mouse model.
Pyrin Inflammasome Activation Abrogates Interleukin-1 Receptor Antagonist, Suggesting a New Mechanism Underlying Familial Mediterranean Fever Pathogenesis
Sussi B. Mortensen,Ann-Brit E. Hansen,Trine H. Mogensen,Marianne A. Jakobsen,Hans C. Beck,Eva B. Harvald,Kate L. Lambertsen,Isik S. Johansen,Ditte C. Andersen
doi : 10.1002/art.41770
Volume 73, Issue 11 p. 2116-2126
Aberrant pyrin inflammasome activity triggers familial Mediterranean fever (FMF) pathogenesis, but the exact mechanism remains elusive and an obstacle to efficient treatment. We undertook this study to identify pyrin inflammasome–specific mechanisms to improve FMF treatment and diagnostics in the future.
Prediction of Differential Pharmacologic Response in Chronic Pain Using Functional Neuroimaging Biomarkers and a Support Vector Machine Algorithm: An Exploratory Study
Eric Ichesco,Scott J. Peltier,Ishtiaq Mawla,Daniel E. Harper,Lynne Pauer,Steven E. Harte,Daniel J. Clauw,Richard E. Harris
doi : 10.1002/art.41781
Volume 73, Issue 11 p. 2127-2137
There is increasing demand for prediction of chronic pain treatment outcomes using machine-learning models, in order to improve suboptimal pain management. In this exploratory study, we used baseline brain functional connectivity patterns from chronic pain patients with fibromyalgia (FM) to predict whether a patient would respond differentially to either milnacipran or pregabalin, 2 drugs approved by the US Food and Drug Administration for the treatment of FM.
Industry Payments to Practicing US Rheumatologists, 2014–2019
Michael S. Putman,Jay E. Goldsher,Cynthia S. Crowson,Alí Duarte-García
doi : 10.1002/art.41896
Volume 73, Issue 11 p. 2138-2144
Payments from the pharmaceutical industry to practicing physicians may influence prescribing behavior. This study was undertaken to investigate the nature, quantity, and geographic distribution of payments to US rheumatologists.
Cardiovascular and Renal Morbidity in Takayasu Arteritis: Comment on the Article by Goel et al
Hsuan-Hsien Liu,Hao-Hung Tsai,James Cheng-Chung Wei
doi : 10.1002/art.41804
Volume 73, Issue 11 p. 2145-2145
Reply
Ruchika Goel,Joht Singh Chandan,Rasiah Thayakaran,Nicola J. Adderley,Krishnarajah Nirantharakumar,Lorraine Harper
doi : 10.1002/art.41809
Volume 73, Issue 11 p. 2145-2146
Noncoding RNAs, Osteoarthritis, and the Microbiome: New Therapeutic Targets? Comment on the Article by Wei et al
Maddalena Sirufo,Lia Ginaldi,Massimo De Martinis
doi : 10.1002/art.41795
Volume 73, Issue 11 p. 2146-2146
Reply
Jie Wei,Yuqing Zhang,Chao Zeng,Guanghua Lei
doi : 10.1002/art.41797
Volume 73, Issue 11 p. 2146-2147
Outcomes and Western Ontario and McMaster Universities Osteoarthritis Index Score Reporting in a Trial of the Efficacy and Safety of Diclofenac–Hyaluronate Conjugate: Comment on the Article by Nishida et al
Daniel L. Riddle
doi : 10.1002/art.41785
Volume 73, Issue 11 p. 2147-2148
Reply
Yoshihiro Nishida,Kazuyuki Kano,Yuji Nobuoka,Takayuki Seo
doi : 10.1002/art.41786
Volume 73, Issue 11 p. 2148-2149
More Steps Forward to Optimize the Dosing of Hydroxychloroquine: Comment on the Article by Petri et al
Jui-Hung Kao,Ting-Yuan Lan,Ko-Jen Li
doi : 10.1002/art.41881
Volume 73, Issue 11 p. 2149-2149
